Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator.

Autor: Vella A; Division of Endocrinology and Diabetes, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA., Freeman JLR; vTv Therapeutics Inc. and vTv Therapeutics LLC, High Point, NC 27265, USA., Dunn I; vTv Therapeutics Inc. and vTv Therapeutics LLC, High Point, NC 27265, USA., Keller K; vTv Therapeutics Inc. and vTv Therapeutics LLC, High Point, NC 27265, USA., Buse JB; Division of Endocrinology and Metabolism, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA., Valcarce C; vTv Therapeutics Inc. and vTv Therapeutics LLC, High Point, NC 27265, USA. cvalcarce@vtvtherapeutics.com.
Jazyk: angličtina
Zdroj: Science translational medicine [Sci Transl Med] 2019 Jan 16; Vol. 11 (475).
DOI: 10.1126/scitranslmed.aau3441
Abstrakt: The therapeutic success of interventions targeting glucokinase (GK) activation for the treatment of type 2 diabetes has been limited by hypoglycemia, steatohepatitis, and loss of efficacy over time. The clinical characteristics of patients with GK-activating mutations or GK regulatory protein (GKRP) loss-of-function mutations suggest that a hepatoselective GK activator (GKA) that does not activate GK in β cells or affect the GK-GKRP interaction may reduce hyperglycemia in patients with type 2 diabetes while limiting hypoglycemia and liver-associated adverse effects. Here, we review the rationale for TTP399, an oral hepatoselective GKA, and its progression from preclinical to clinical development, with an emphasis on the results of a randomized, double-blind, placebo- and active-controlled phase 2 study of TTP399 in patients with type 2 diabetes. In this 6-month study, TTP399 (800 mg/day) was associated with a clinically significant and sustained reduction in glycated hemoglobin, with a placebo-subtracted least squares mean HbA 1c change from baseline of -0.9% ( P < 0.01). Compared to placebo, TTP399 (800 mg/day) also increased high-density lipoprotein cholesterol (3.2 mg/dl; P < 0.05), decreased fasting plasma glucagon (-20 pg/ml; P < 0.05), and decreased weight in patients weighing ≥100 kg (-3.4 kg; P < 0.05). TTP399 did not cause hypoglycemia, had no detrimental effect on plasma lipids or liver enzymes, and did not increase blood pressure, highlighting the importance of tissue selectivity and preservation of physiological regulation when targeting key metabolic regulators such as GK.
(Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.)
Databáze: MEDLINE
Externí odkaz: